Enteric fever caused by typhoidal Salmonella serovars remains endemic in many low- and middle-income countries, particularly in sub-Saharan Africa and South and South‑East Asia. The principal agents are Salmonella Typhi and Salmonella Paratyphi A (SPA). Currently there are no licensed vaccines for SPA, leaving antimicrobials as the primary therapeutic option. While multidrug-resistant (MDR) S. Typhi has become increasingly prevalent, MDR in SPA had not been detected historically prior to the findings reported here.
This report presents genomic epidemiology and antimicrobial resistance profiling of SPA isolates from returned travellers to Australia and their close contacts, aiming to link travel-associated epidemiology with genomic data to inform surveillance and empirical treatment guidance.
The analysis covers 208 SPA cases collected from 2018 through 2025. Cases were notifiable in Australia and included returned travellers and close contacts. Genomic data for the isolates have been deposited under MDU PHL BioProject PRJNA857539. Supplementary Table 1 (as reported by the authors) lists isolate-level details including accessions, sequencing technology, year of collection, genotype and antimicrobial resistance (AMR) profile.
Whole-genome analyses identified 15 unique SPA genotypes among the 208 isolates. These genotypes showed correlation with the geographic regions reported by patients for travel exposure, indicating that genomic typing reflected likely sources of infection in returned travellers. The presence of multiple genotypes emphasizes ongoing global diversity and multiple regional lineages contributing to imported SPA cases.
Overall, the incidence of acquired antimicrobial resistance among the sampled SPA isolates was low: only a single isolate carried acquired resistance genes. Nonetheless, mutations in the quinolone resistance determining regions (QRDRs) were highly prevalent, detected in 95.7% of isolates across the genotypes. The high frequency of QRDR mutations signals reduced susceptibility to fluoroquinolones is widespread among imported SPA isolates.
A single isolate recovered from a traveller returning from India exhibited resistance to multiple first-line antibiotics: ampicillin, amoxicillin–clavulanic acid, ceftriaxone, azithromycin and ciprofloxacin. Genomic analysis showed this isolate carried a plasmid encoding an extended‑spectrum beta‑lactamase (blaCTX-M-231), two macrolide resistance genes (mphA and ermB) and a plasmid-associated quinolone resistance gene (qnrS1). This combination of resistance determinants conferred resistance across several antibiotic classes and represents an important signal of emerging multidrug resistance in SPA associated with international travel.
Elements of the SPA pangenome were examined. The study found stable maintenance of small plasmids encoding hypothetical proteins in four genotypes. Additionally, copy number variation was observed in genes encoding surface antigen biosynthesis in six genotypes. These genetic variations reflect plasmid dynamics and genomic plasticity within SPA lineages sampled from returned travellers.
Surface antigen biosynthesis genes are targets for one of the two SPA vaccines currently in development. The detected copy number variation in these biosynthesis genes across multiple genotypes raises the possibility that antigenic variation could influence vaccine efficacy. The authors note that genomic surveillance linking antigenic gene variation with circulating genotypes could inform vaccine design and expected performance against diverse SPA strains.
The SPA genomes from this study are available via MDU PHL BioProject PRJNA857539. Individual isolate metadata and sequencing details are reported in Supplementary Table 1. Data collection complied with the Victorian Public Health and Wellbeing Act 2008, and ethical approval was provided by the University of Melbourne Human Research Ethics Committee (reference number 2024-30320-59894-3). The authors declared no competing interests.
Note: Methodological detail beyond what was summarized (for example, specific sequencing platforms per isolate beyond the statement that ONT sequencing technology details are in Supplementary Table 1, or analytic pipelines) are reported by the authors in supplemental material; those procedural details are not reproduced here.
Genomic surveillance of 208 SPA cases in returned travellers to Australia from 2018–2025 identified 15 genotypes aligned with travel regions, widespread QRDR mutations (95.7% of isolates), and generally low rates of acquired resistance genes with one notable multidrug-resistant isolate harboring blaCTX-M-231, mphA, ermB, and qnrS1. These findings underscore the value of linking epidemiological travel data with genomic analyses to monitor the emergence and spread of AMR in SPA and to inform empirical treatment recommendations for returned travellers. Continued genomic surveillance is warranted, particularly given the potential for antigenic variation to affect upcoming SPA vaccines and the detection of plasmid-mediated multidrug resistance in at least one imported case.